非增强MRI作为肝细胞癌监测工具:与超声的比较
该前瞻性队列纳入382例高危患者,比较非增强MRI(DWI联合T2WI)与超声监测HCC的性能。非增强MRI每病灶和每次检查灵敏度分别为77.1%和79.1%,均高于超声的25.0%和27.9%(p<0.001),特异度97.9%对94.5%亦有显著差异(p<0.001)。非增强MRI扫描时间<6分钟且无对比剂相关风险,是高危患者HCC监测的有前景选择。
要点
- 非增强MRI监测HCC灵敏度显著高于超声(79.1%对27.9%,p<0.001)。
- 非增强MRI特异度和阴性预测值均优于超声。
- 非增强MRI扫描时间<6分钟,无对比剂相关风险。
核心结论
- 非增强MRI在高危患者HCC监测中性能显著优于超声,且扫描时间短、无对比剂相关风险,是有前景的监测选择。
研究设计与样本
- 前瞻性队列研究,纳入382例高危患者,接受1至3轮配对钆塞酸增强MRI与超声检查。
- 非增强MRI由DWI和T2WI模拟并回顾性分析,病灶≥1 cm且显示弥散受限或轻中度T2高信号判为阳性。
- HCC诊断基于组织学和/或影像学,采用广义估计方程评估灵敏度、阳性预测值、特异度和阴性预测值。
主要发现
- 非增强MRI每病灶和每次检查灵敏度分别为77.1%和79.1%,高于超声的25.0%和27.9%(p<0.001)。
- 非增强MRI特异度为97.9%,超声为94.5%,差异显著(p<0.001)。
- 非增强MRI阴性预测值为99.1%,高于超声的96.9%。
- 非增强MRI每病灶和每次检查阳性预测值分别为56.9%和61.8%,高于超声的16.7%和17.7%。
关键数值与推荐
- 非增强MRI阳性判定标准:病灶≥1 cm且显示弥散受限或轻中度T2高信号。
- 非增强MRI估计扫描时间<6分钟。
临床怎么用
- 对超声监测不充分的高危患者,可考虑采用非增强MRI(DWI联合T2WI)作为替代监测手段。
- 非增强MRI扫描时间短且无对比剂相关风险,适合需要替代影像监测的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recently revised international guidelines for hepatocellular carcinoma (HCC) suggest that patients with inadequate ultrasonography be assessed by alternative imaging modalities. Non-enhanced MRI has potential as a surveillance tool based on the short scan times required and the absence of contrast agent-associated risks. This study compared the performance of non-enhanced MRI and ultrasonography for HCC surveillance in high-risk patients. METHODS: We included 382 high-risk patients in a prospective cohort who underwent 1 to 3 rounds of paired gadoxetic acid-enhanced MRI and ultrasonography. Non-enhanced MRI, consisting of diffusion-weighted imaging (DWI) and T2-weighted imaging, was simulated and retrospectively analyzed, with results considered positive when lesion(s) ≥1 cm showed diffusion restriction or mild-moderate T2 hyperintensity. Ultrasonography results were retrieved from patient records. HCC was diagnosed histologically and/or radiologically. Sensitivity, positive predictive value (PPV), specificity, and negative predictive value (NPV) were evaluated using generalized estimating equations. RESULTS: Forty-eight HCCs were diagnosed in 43 patients. Per-lesion and per-exam sensitivities of non-enhanced MRI were 77.1% and 79.1%, respectively, which were higher than those achieved with ultrasonography (25.0% and 27.9%, respectively, p <0.001). Specificities of non-enhanced MRI (97.9%) and ultrasonography (94.5%) differed significantly (p <0.001). NPV was higher for non-enhanced MRI (99.1%) than ultrasonography (96.9%). Per-lesion and per-exam PPVs were higher for non-enhanced MRI (56.9% and 61.8%, respectively) than for ultrasonography (16.7% and 17.7%, respectively). The estimated scan time of non-enhanced MRI was <6 min. CONCLUSION: Based on its good performance, short scan times, and the lack of contrast agent-associated risks, non-enhanced MRI is a promising option for HCC surveillance in high-risk patients. LAY SUMMARY: Recently revised international guidelines for hepatocellular carcinoma (HCC) suggest that selected patients with inadequate surveillance on ultrasonography be assessed by alternative imaging modalities such as computed tomography or magnetic resonance imaging (MRI). Herein, we show that MRI without contrast agents performed significantly better than ultrasonography for HCC surveillance in high-risk patients. Given this good performance, as well as short scan times and the lack of contrast agent-associated risks, non-enhanced MRI is a promising option for HCC surveillance in high-risk patients.
引用
- Park HJ, Jang HY, Kim SY, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol. 2019. PMID: 31836549. doi:10.1016/j.jhep.2019.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。